Pharma Kings: LLY, MRK, VRTX, AMLX & IMRA Hit New Heights Again
Phamacy stocks rose 1.29% among S&P 500 sectors on Monday, the third-highest gainer behind Systems Software (+1.82%) and Technology Hardware sectors (+1.44%).
We have observed that several Healthcare stocks have been hitting new year highs recently: for example: $Amylyx Pharmaceuticals, Inc.(AMLX)$ , $Imara Inc.(IMRA)$ , $Vertex Pharmaceuticals(VRTX)$ , $Eli Lilly and(LLY)$ , $Merck(MRK)$On Monday, $(IMRA)$ was up 15%, $(AMLX)$ was up 1.87%, $(VRTX)$ rose 3.51%, $(LLY)$ up 2.09% and $(MRK)$ was up 1.78%.
1. The fundamentals of the five companies are as follows:
Source from seeking alpha
As of Monday, the 3-year Return data of the five companies is as follows: $Imara Inc.(IMRA)$ is the strongest in 2022. All five companies also outperformed the broader market.
Source from seeking alpha
For the current rating of 5 companies, most agencies have given a buy or hold rating. Only $Eli Lilly and(LLY)$ see a sell by SA's Authors.
Source from seeking alpha
2. Take a closer look at the reasons for 5 companies' rise:Macro beta factors benefits:
The US represents a 45% share of the global pharmaceutical market, According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues of $1.5 trillion in 2023.
The COVID-19 pandemic brought the pharmaceutical sector into the limelight as the demand for drugs and vaccines observed a sharp spike.Although the equity market has come under pressure in the recent past due to raging inflation, geopolitical tensions, and rising interest rates, the best pharmaceutical stocks have held their ground.
In addition, as vaccines will be transferred from the system managed by the US federal government to the commercial market, it is expected that the supply of Covid-19 vaccines in the United States next year will shift from free government provision to a commercial (self-pay + medical insurance + commercial newspaper) sales model, vaccines may be Ushering in a wave of price increases, related pharmaceutical or medical service companies ushered in good news.
Pfizer/BioNTech and Moderna have said that the company's covid-19 vaccine products will increase equivalent to 4 times the previous price.
According to Grand View Research, the pharmaceutical sector will continue to experience secular tailwinds like growth in population and aging, providing an opportunity for the industry to compound its sales annually by 11.3% till 2028.
3. Alpha factors that affect each company's stock price rise:
Headquartered in Indianapolis, Indiana, Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company.LLYwill announce its earnings results before the market opens on Tuesday, November 1st.
Analysts expect the company to announce earnings of $1.95 per share for the quarter. Eli Lilly and has set its FY 2022 guidance at $7.90-$8.05 EPS.
On the news, the approval of Biogen's new generation of AZD drugs and the relaxation of willingness to pay by CMS are positive for LLY's stock price. In terms of financial reports, the company's product Tirzepatide sales exceeded expectations, which will also stimulate LLY's stock price to continue to rise.
Eli Lilly last issued its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.80 by ($0.55). The business had revenue of $6.49 billion during the quarter, compared to the consensus estimate of $6.85 billion. Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%.
LLY received an overall rating of 97, which means that it scores higher than 97% of stocks. Additionally, Eli Lilly And Co scored a 89 in the Healthcare sector, ranking it higher than 89% of stocks in that sector.Overall market sentiment has been high on Eli Lilly And Co (LLY) stock lately. LLY receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
2.$Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)$
VRTX is working on developing non-opioid analgesics to treat chronic neuropathic pain. The market for pain medication is a significant one, but developing an effective non-opioid analgesic has been challenging for many pharmaceutical companies.
VRTX has also announced that it will file the Biologics License Application (BLA) for exagamglogene autotemcel (exa-cel) by the start of November and anticipates completing the submission by Q1 2023. This was a positive development as investors did not expect the filing to be done by Q4 2023. Exa-cel is aimed towards treating sickle cell disease.
VRTX has also been given the go-ahead from the FDA to initiate the first-in-human trial for VX-634, which is a small molecule AAT corrector.For FY22, VRTX has forecasted sales from CF treatments to be around $8.6 billion to $8.8 billion.
Analysts expect VRTX to continue growing its therapy pipeline. The company has strong growth potential over the next 5-10 years, making it one of the best pharmaceutical stocks to hold in the long run.
VRTX has a nice breakout on Monday with above-average volume. this company will announce earnings later this week. The company's traditional business is still exceeding expectations in Q2, and with the new transformation direction and various good news, the price is expected to take off.
MRK will report third-quarter 2022 results on Oct 27 before market open. In the last reported quarter, the company delivered an earnings surprise of 18.23%.
The large drugmaker’s performance beat earnings expectations in each of the trailing four quarters. The company delivered a four-quarter earnings surprise of 16.79%, on average.
AstraZeneca and Merck formed a profit-sharing deal to co-market Lynparza and Koselugo in July 2017.
After the U.S. Covid-19 mRNA vaccine is going to commercialization, the price may increase by 4 times by $110 to $130 dollars per dose. It is expected that After the commercialization of the vaccine, the new volume x price can still maintain a considerable market size and bring long-term stable cash flow to the company.
Merck’s Earnings ESP is -1.04% as the Zacks Consensus Estimate of $1.69 per share is higher than the Most Accurate Estimate of $1.67 per share.
4.$Amylyx Pharmaceuticals, Inc.(AMLX)$
Amylyx Pharmaceuticals, Inc. is a Cambridge, Massachusetts-based company that is focused on treating neurodegenerative diseases.
In a research note issued on October 3, Neena Bitritto-Garg at Citi increased the target price for AMLXfrom $48 to $50 and maintained a Buy rating on the stock. The analyst made changes to her financial model following the full approval of Relyvrio from the FDA for treating amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. Garg gave positive commentary on the $158,000 per year net price for the treatment, which is 7% lower than the net annual price of $170,000 for competitor Edaravone.
The analyst believes that the attractive pricing will result in positive feedback from the patients and advocacy groups, bringing the drug into the limelight. This will translate into higher demand and sales.
Experts believe that AMLX stock is trading at an attractive valuation due to the overhang related to financing and the uncertainty surrounding the PHOENIX drug trials. This provides a good opportunity for investors to take a long position in the stock.
Imara Inc. ’s recent news is merger with Enliven Therapeutics,and IMARA Inc. next reports earnings on November 8.
IMARA Inc. major shareholder Ra Capital Management, L.P. acquired 26,460 shares of the stock at an average price of $3.91 per share, with a total value of $103,458.60. on October 24th.
The shares were bough Following the completion of the transaction, the insider now owns 3,220,825 shares in the company, valued at $12,593,425.75.
Ra Capital Management, L.P. also recently made the following trade(s):
- On October 21st, bought 48,100 shares at an average price of $3.92 per share, with a total value of $188,552.00.
- On October 19th，acquired 125,726 shares at an average price of $3.89 per share, with a total value of $489,074.14.
- On October 17th, purchased 145,672 shares at an average cost of $3.36 per share, with a total value of $489,457.92.IMARA Inc.
- MRK gets a Sentiment Score of Neutral from InvestorsObserver and receives an average analyst recommendation of Buy.
4. Other large healthcarestocks to watch:$Bristol-Myers Squibb(BMY)$ ,$Johnson & Johnson(JNJ)$ ,$Novartis AG(NVS)$ ,$Pfizer(PFE)$
Source from seeking alpha
Source from seeking alpha
Source from seeking alpha
Some more related stocks you may like：$$Amgen(AMGN)$ , $Novo-Nordisk A/S(NVO)$ ,$AbbVie(ABBV)$ ,$Regeneron Pharmaceuticals(REGN)$ ,$AstraZeneca PLC(AZN)$ , $Sanofi SA(SNY)$ ,$Gilead Sciences(GILD)$,$CVS Health(CVS)$.
Please join to discuss which healthcare stock you like the most?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Health Industry